CNR Institutional Research Information System

MELILLO, ROSA MARINA

MELILLO, ROSA MARINA  

Istituto di Endocrinologia e Oncologia Sperimentale ''G. Salvatore'' - IEOS  

Mostra records
Risultati 1 - 20 di 72 (tempo di esecuzione: 0.121 secondi).
Titolo Data di pubblicazione Autore(i) File
A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. 1-gen-2007 Salvatore G; Nappi TC; Salerno P; Jiang Y; Garbi C; Ugolini C; Miccoli P; Basolo F; Castellone MD; Cirafici AM; Melillo RM; Fusco A; Bittner ML; Santoro M.
A new germline point mutation in Ret exon 8 (cys515ser) in a family with medullary thyroid carcinoma. 1-gen-2008 Fazioli F; Piccinini G; Appolloni G; Bacchiocchi R; Palmonella G; Recchioni R; Pierpaoli E; Silvetti F; Scarpelli M; Bruglia M; Melillo RM; Santoro M; Boscaro M; Taccaliti A.
Activation of the Erk8 MAP kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene 1-gen-2006 Iavarone C.; Acunzo M.; Carlomagno F.; Catania A.; Melillo R.M.; Carlomagno M.S.; Santoro M.;Chiariello M.
Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer 1-gen-2011 Avilla, Elvira; Guarino, Valentina; Visciano, Carla; Liotti, Federica; Svelto, Maria; Svelto, Maria; Krishnamoorthy, Gnanaprakasam; Franco, Renato; Melillo, ROSA MARINA; Melillo, ROSA MARINA
Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. 1-gen-2004 Castellone MD; Celetti A; Guarino V; Cirafici AM; Basolo F; Giannini R; Medico E; Kruhoffer M; Orntoft TF; Curcio F; Fusco A; Melillo RM; Santoro M.
Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. 1-gen-2004 Castellone MD; Celetti A; Guarino V; Cirafici AM; Basolo F; Giannini R; Medico E; Kruhoffer M; Orntoft TF; Curcio F; Fusco A; Melillo RM; Santoro M.
AXL is a novel predictive factor and therapeutic target for radioactive iodine refractory thyroid cancer 1-gen-2019 Collina, F; La Sala, L; Liotti, F; Prevete, N; La Mantia, E; Chiofalo, Mg; Aquino, G; Arenare, L; Cantile, M; Liguori, G; Di Gennaro, F; Pezzullo, L; Losito, Ns; Vecchio, G; Botti, G; Melillo, Rm; Franco, R
AXL is an oncotarget in human colorectal cancer 1-gen-2015 Martinelli, Erika; Martini, Giulia; Cardone, Claudia; Troiani, Teresa; Liguori, Giuseppina; Vitagliano, Donata; Napolitano, Stefania; Morgillo, Floriana; Rinaldi, Barbara; Melillo, ROSA MARINA; Liotti, Federica; Nappi, Anna; Bianco, Roberto; Berrino, Liberato; Ciuffreda Loreta, Pia; Ciardiello, Davide; Iaffaioli, Vincenzo; Botti, Gerardo; Ferraiolo, Fiorella; Ciardiello, Fortunato
Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma. 1-gen-2006 Moretti, S; Macchiarulo, A; De Falco, V; Avenia, N; Barbi, F; Carta, C; Cavaliere, A; Melillo, Rm; Passeri, L; Santeusanio, F; Tartaglia, M; Santoro, M; Puxeddu, E
Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. 1-gen-2007 De Falco V; Guarino V; Avilla E; Castellone MD; Salerno P; Salvatore G; Faviana P; Basolo F; Santoro M;Melillo RM.
BRAF is a therapeutic target in aggressive thyroid carcinoma. 1-gen-2006 Salvatore G; De Falco V; Salerno P; Nappi TC; Pepe S; Troncone G; Carlomagno F; Melillo RM; Wilhelm SM; Santoro M.
Critical role of the HMGI(Y) proteins in adipocytic cell growth and differentiation. 1-gen-2001 Melillo, Rm; Pierantoni, Gm; Scala, S; Battista, S; Fedele, M; Stella, A; De Biasio, Mc; Chiappetta, G; Fidanza, V; Condorelli, G; Santoro, M; Croce, Cm; Viglietto, G; Fusco, A
CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas. 1-gen-2012 Torregrossa, L; Giannini, R; Borrelli, N; Sensi, E; Melillo, Rm; Leocata, P; Materazzi, G; Miccoli, P; Santoro, M; Basolo, F
Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. 1-gen-2002 Viglietto, G; Motti, Ml; Bruni, P; Melillo, Rm; D'Alessio, A; Califano, D; Vinci, F; Chiappetta, G; Tsichlis, P; Bellacosa, A; Fusco, A; Santoro, M
Different mutations of the RET gene cause different human tumoral diseases 1-gen-1999 Santoro, M; Melillo, Rm; Carlomagno, F; Visconti, R; De Vita, G; Salvatore, G; Fusco, A; Vecchio, G
Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade. 1-gen-2001 Melillo, Rm; Santoro, M; Ong, Sh; Billaud, M; Fusco, A; Hadari, Yr; Schlessinger, J; Lax, I
Dysfunction of the RET receptor in human cancer. 1-gen-2004 Santoro, M; Carlomagno, F; Melillo, Rm; Fusco, A
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). 1-gen-2003 Carlomagno F. ; Vitagliano D. ; Guida T. ; Basolo F. ; Castellone M.D. ; Melillo R.M. ; Fusco A. ; Santoro M.
Formyl peptide receptor 1 suppresses gastric cancer angiogenesis and growth by exploiting inflammation resolution pathways 1-gen-2017 Prevete, Nella; Liotti, Federica; Illiano, Anna; Amoresano, Angela; Pucci, Piero; de Paulis, Amato; Melillo, Rosa Marina
Formyl peptide receptors at the interface of inflammation, angiogenesis and tumor growth 1-gen-2015 Prevete, Nella; Liotti, Federica; Marone, Gianni; Melillo, Rosa Marina; De Paulis, Amato